We are live on ! Find out more
CPXX

CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX

Delisted

CPXX was delisted on the 11th of July, 2016.

Back to rankings

0 hedge funds and large institutions have $0 invested in CELATOR PHARMACEUTICALS INC. COMMON STOCK in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 117 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 119 → 0 (-119)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $944M → $0 (-$944M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 117

Holders
–
Holders Change
-119
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
117
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CC
Caxton Corporation
New Jersey
-$67.4M
2
AAM
Alpine Associates Management
Florida
-$66.9M
3
MF
Magnetar Financial
Illinois
-$48M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$37.9M
5
ACA
Avoro Capital Advisors
New York
-$33.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
1
Caxton Corporation
New Jersey
– -$67.4M -2,232,272 Closed
AAM
2
Alpine Associates Management
Florida
– -$66.9M -2,215,566 Closed
MF
3
Magnetar Financial
Illinois
– -$48M -1,590,000 Closed
Vanguard Group
4
Vanguard Group
Pennsylvania
– -$37.9M -1,256,026 Closed
ACA
5
Avoro Capital Advisors
New York
– -$33.9M -1,124,666 Closed
AA
6
AQR Arbitrage
Connecticut
– -$33.5M -1,111,391 Closed
Fidelity Investments
7
Fidelity Investments
Massachusetts
– -$30.9M -1,025,300 Closed
Deutsche Bank
8
Deutsche Bank
Germany
– -$30.1M -996,192 Closed
GCL
9
Glazer Capital LLC
New York
– -$29.1M -965,785 Closed
GF
10
Gabelli Funds
New York
– -$25.9M -856,626 Closed
BFA
11
BlackRock Fund Advisors
California
– -$25.7M -851,430 Closed
OAM
12
Oxford Asset Management
United Kingdom
– -$25.6M -849,400 Closed
PA
13
Perceptive Advisors
New York
– -$25.3M -838,400 Closed
CC
14
Coastland Capital
California
– -$22.6M -750,000 Closed
BIT
15
BlackRock Institutional Trust
California
– -$20.9M -693,728 Closed
GCIA
16
Gabelli & Co Investment Advisers
New York
– -$19.6M -649,249 Closed
GLAM
17
Gardner Lewis Asset Management
Pennsylvania
– -$19.1M -633,448 Closed
Morgan Stanley
18
Morgan Stanley
New York
– -$18.3M -607,639 Closed
WIC
19
Water Island Capital
New York
– -$16.9M -559,600 Closed
JP Morgan Chase
20
JP Morgan Chase
New York
– -$16.4M -542,706 Closed
State Street
21
State Street
Massachusetts
– -$16.2M -536,802 Closed
Allianz Asset Management
22
Allianz Asset Management
Germany
– -$15.8M -523,500 Closed
Alyeska Investment Group
23
Alyeska Investment Group
Illinois
– -$15.2M -502,849 Closed
SAM
24
Sandell Asset Management
New York
– -$13.5M -448,293 Closed
SG Americas Securities
25
SG Americas Securities
New York
– -$13.2M -436,207 Closed
1
2 3 4 5

CPXX Hedge Fund Activity: Q3 2016 in Review

0 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) for Q3 2016, worth a combined $0 — down 100% from $944M a quarter earlier.

Sellers outnumbered buyers: 117 funds closed out of CPXX and 0 opened new positions — a net loss of 117 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Caxton Corporation, exiting entirely with an estimated $67.4M sold.

  • 0 institutional investors held CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) as of Q3 2016, down from 119 in Q2 2016.
  • Funds reported $0 of CELATOR PHARMACEUTICALS INC. COMMON STOCK stock for Q3 2016, down 100% quarter-over-quarter.
  • 0 funds opened new CELATOR PHARMACEUTICALS INC. COMMON STOCK positions in Q3 2016 and 117 closed out, a net change of -117 holders.
  • The largest CELATOR PHARMACEUTICALS INC. COMMON STOCK seller in Q3 2016 was Caxton Corporation, an estimated $67.4M sold.

Based on aggregated 13F filings for Q3 2016.